WallStSmart

CVRx Inc (CVRX)vsMerck & Company Inc (MRK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 111235% more annual revenue ($65.77B vs $59.07M). MRK leads profitability with a 13.6% profit margin vs -89.1%. MRK earns a higher WallStSmart Score of 50/100 (D+).

CVRX

Avoid

29

out of 100

Grade: F

Growth: 7.3Profit: 2.0Value: 6.7Quality: 4.5
Piotroski: 3/9Altman Z: -7.47

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 2.7Quality: 5.0
Piotroski: 3/9Altman Z: 2.30
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CVRXUndervalued (+71.4%)

Margin of Safety

+71.4%

Fair Value

$21.26

Current Price

$5.38

$15.88 discount

UndervaluedFair: $21.26Overvalued
MRKSignificantly Overvalued (-49.3%)

Margin of Safety

-49.3%

Fair Value

$80.88

Current Price

$120.79

$39.91 premium

UndervaluedFair: $80.88Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CVRX1 strengths · Avg: 8.0/10
Revenue GrowthGrowth
19.6%8/10

19.6% revenue growth

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$285.64B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

Areas to Watch

CVRX4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$156.03M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-180.9%2/10

ROE of -180.9% — below average capital efficiency

MRK4 concerns · Avg: 3.5/10
P/E RatioValuation
32.6x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Debt/EquityHealth
1.073/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : CVRX

The strongest argument for CVRX centers on Revenue Growth. Revenue growth of 19.6% demonstrates continued momentum.

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bear Case : CVRX

The primary concerns for CVRX are EPS Growth, Market Cap, Piotroski F-Score. Debt-to-equity of 2.03 is elevated, increasing financial risk.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.

Key Dynamics to Monitor

CVRX profiles as a growth stock while MRK is a value play — different risk/reward profiles.

CVRX carries more volatility with a beta of 0.77 — expect wider price swings.

CVRX is growing revenue faster at 19.6% — sustainability is the question.

MRK generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (50/100 vs 29/100). CVRX offers better value entry with a 71.4% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

CVRx Inc

HEALTHCARE · MEDICAL DEVICES · USA

CVRx, Inc. develops implantable technology for the treatment of patients with high blood pressure / hypertension and heart failure.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Want to dig deeper into these stocks?